229 related articles for article (PubMed ID: 35464865)
1. Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma.
Wang H; Cui J; Yu J; Huang J; Li M
Front Genet; 2022; 13():855940. PubMed ID: 35464865
[TBL] [Abstract][Full Text] [Related]
2. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
3. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
6. An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma.
Li Y; Sun X
Front Genet; 2022; 13():768971. PubMed ID: 35368654
[No Abstract] [Full Text] [Related]
7. Construction of a Nomogram Based on a Hypoxia-Related lncRNA Signature to Improve the Prediction of Gastric Cancer Prognosis.
Chen Q; Hu L; Chen K
Front Genet; 2020; 11():570325. PubMed ID: 33193668
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of lncRNAs related to fatty acid metabolism in lung adenocarcinoma and their correlation with tumor microenvironment based on bioinformatics analysis.
Pan YQ; Xiao Y; Long T; Liu C; Gao WH; Sun YY; Liu C; Shi YJ; Li S; Shao AZ
Front Oncol; 2022; 12():1022097. PubMed ID: 36300102
[TBL] [Abstract][Full Text] [Related]
9. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
10. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
11. Construction of a lung adenocarcinoma prognostic model based on N6-methyl-adenosine-related long noncoding RNA and screening of potential drugs based on this model.
Hou Q; Zhong Y; Liu L; Wu L; Liu J
Anticancer Drugs; 2022 Apr; 33(4):371-383. PubMed ID: 35213857
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
Jin D; Song Y; Chen Y; Zhang P
Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Novel Six-lncRNA-Based Prognostic Model for Lung Adenocarcinoma.
Yang L; Wu Y; Xu H; Zhang J; Zheng X; Zhang L; Wang Y; Chen W; Wang K
Front Oncol; 2021; 11():775583. PubMed ID: 35111670
[TBL] [Abstract][Full Text] [Related]
15. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
16. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
17. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
18. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
19. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
Zhou J; Wang X; Li Z; Jiang R
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
[TBL] [Abstract][Full Text] [Related]
20. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]